维普期刊资源整合服务平台（V6.5）

91篇 您的检索式：作者名="Negrier"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial显示文摘	Brian I Rini Bernard Escudier Piotr Tomczak Andrey Kaprin Cezary Szczylik Thomas E Hutson M Dror Michaelson Vera A Gorbunova Martin E Gore Igor G Rusakov Sylvie Negrier Yen-Chuan Ou Daniel Castellano Ho Yeong Lim Hirotsugu Uemura Jamal Tarazi David Cella	2011	The Lancet . 2011 (9807)2011，，9807：	2
2	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial显示文摘	Brian I Rini Bernard Escudier Piotr Tomczak Andrey Kaprin Cezary Szczylik Thomas E Hutson M Dror Michaelson Vera A Gorbunova Martin E Gore Igor G Rusakov Sylvie Negrier Yen-Chuan Ou Daniel Castellano Ho Yeong Lim Hirotsugu Uemura Jamal Tarazi David Cella	2011	The Lancet2011，，9807：	2
3	Safety and efficacy of subcutaneous and continuous intravenous itffusion rlL-2 in patients with metastatic renal cell carcinoma 显示文摘	Geertsen PF Gore ME Negrier S	2004	Br J Cancer2004，90，6：	1
4	The treatment of bleeding in ac quired haemophilia with recombinant factorⅦa: a multicentre study 显示文摘	Hay CR Negrier C Ludiam CA	1997	Thromb Haemost1997，78，：	1
5	Sequential sorafenib and sunitinib for renal cell carcinoma显示文摘	Sablin M P Negrier S Ravaud A	2009	J Urol2009，182，1：	1
6	Medroxyprogeste- rone,interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results from a randomized controlled trial 显示文摘	Negrier S Perol D Ravaud C	2007	Cancer2007，110，11：	1
7	Phase ID trial of bev-acizumab plus interferon alfa-2a in patients with metastatic renalcell carcinoma ( AVOREN ) : Final analysis of overall survival显示文摘	Escudier B Bellmunt J Negrier S	2010	J Clin Oncol2010，28，13：	1
8	Serum level of interleukin-6 as a prognosis factor in metastatic r e nal cellcarcinoma显示文摘	Blay JY Negrier M Comb aret V etal	1992	Cancer Res1992，52，：	1
9	Safety and pharmacokinetics of anovel recombinant fusion protein linking coagulation factor IX with albumin(rIX-FP) in hemophilia B patients显示文摘	Santagostino E Negrier C Klamroth R	2012	Blood2012，，120：	1
10	Treatment of verrucous carcinoma with recombinant alfa-interferon显示文摘	Risse L Negrier P Dang PM	1995	Dermatology1995，190，：	1
11	Phase Ⅲ trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN):final analysis of overall survival显示文摘	ESCUDIER B BELLMUNT J NEGRIER S	2010	J Clin Oncol2010，28，13：	1
12	Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival 显示文摘	Escudier B Bellmunt J Negrier S	2010	J Clin Oncol2010，28，13：	1
13	Serum Levels of interleukin-6 as a prognosis factor in matastatic renal cell carcimoma显示文摘	BLAY JY NEGRIER M COMBARET V	1992	Cancer Res1992，52，2：	1
14	Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients 显示文摘	Santagostino E Negrier C Klamroth R	2012	Blood2012，120，12：	1
15	The treatment of bleeding in acquired haemophilia with recombinant factor Ⅶ a: a multicenter study显示文摘	Hay CRM Negrier C Ludlam CA	1997	Throm Haemost1997，78，6：	1
16	Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mR- CC)? Results of the randomized TORAVA phase II trial 显示文摘	Escudier B J Negrier S Gravis G	2010	J Clin Oncol (Meeting Abstracts)2010，28，15：	1
17	Gene therapy for hemophilia? Yes显示文摘		2004	J Thromb Haemost2004，2，：	1
18	Recombinant hu- man interleukin-2 recombinant human interferonalfa-2a or both in metastatic renal cell careinoma显示文摘	NEGRIER S ESCUDIER B LASSET C	2008	Engl J Med2008，338，：	1
19	PhaseⅢtrial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma(AVOREN):final analysis of overall survival显示文摘	Escudier B Bellmunt J Negrier S	2010	J Clin Oncol2010，28，13：	1
20	Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up显示文摘	Rouviere O Bouvier R Negrier S	2006	Nat Clin Pract Oncol2006，3，：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示